BIND Therapeutics and AstraZeneca have signed global development and commercialisation agreement for Accurin cancer nanomedicine.

Accurin is a targeted and programmable cancer nanomedicine from BIND’s medicinal nanoengineering platform, based on a molecularly targeted kinase inhibitor developed by AstraZeneca.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BIND president and CEO Scott Minick said that a year ago the company started several feasibility projects with major pharmaceutical companies.

"Our collaboration with AstraZeneca is the first one completed and had very successful results. Due to the advanced nature of this program, we now plan to move an Accurin with optimised therapeutic properties quickly into product development," Minick said.

"Accurin is a targeted and programmable cancer nanomedicine from BIND’s medicinal nanoengineering platform, based on a molecularly targeted kinase inhibitor developed by AstraZeneca."

According to the agreement, the companies will jointly work to complete investigational new drug-enabling studies of the lead Accurin, which was identified in an earlier feasibility programme.

The development and commercialisation will then be led by AstraZeneca, and BIND will lead manufacturing during the development phase.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
See Also:

BIND is eligible for an upfront payment, $69m worth pre-approval milestone payments, over $130m in regulatory and sales milestones and other payments in addition to sales-based royalties.

AstraZeneca oncology innovative medicines unit head Susan Galbraith said; "Our oncology teams are actively exploring a range of platforms to deliver targeted therapies, with a strategic focus on unlocking the significant potential of nanoparticles as an approach to cancer treatment."

Accurins were developed with superior target selectivity and the potential to improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders.